These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17703641)

  • 1. Early retirement and the influence on healthcare budgets and insurance premiums in a diabetes population.
    Walzer S
    Vasc Health Risk Manag; 2007; 3(3):331-41. PubMed ID: 17703641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Funding savings needed for health expenses for persons eligible for Medicare.
    Fronstin P; Salisbury D; VanDerhei J
    EBRI Issue Brief; 2010 Dec; (351):1-14. PubMed ID: 21319573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Savings needed to fund health insurance and health care expenses in retirement: findings from a simulation model.
    Fronstin P; Salisbury D; VanDerhei J
    EBRI Issue Brief; 2008 May; (317):1-2, 4-27. PubMed ID: 18630312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SCHIP premiums, enrollment, and expenditures: a two state, competing risk analysis.
    Marton J; Ketsche PG; Zhou M
    Health Econ; 2010 Jul; 19(7):772-91. PubMed ID: 19582698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redistributional consequences of community rating.
    Goldman DP; Leibowitz A; Buchanan JL; Keesey J
    Health Serv Res; 1997 Apr; 32(1):71-86. PubMed ID: 9108805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing potential enrollment and budgetary effects of SCHIP premiums: findings from Arizona and Kentucky.
    Kenney G; Marton J; McFeeters J; Costich J
    Health Serv Res; 2007 Dec; 42(6 Pt 2):2354-72. PubMed ID: 17995547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validating a Budget Impact Model Using Payer Insight and Claims Data: A Framework and Case Study.
    Hung A; Slejko JF; Lugo A; Shaya F; Haines ST; Mullins CD
    J Manag Care Spec Pharm; 2019 Aug; 25(8):913-921. PubMed ID: 31347981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical policies: effects of financial incentives for prescribers.
    Rashidian A; Omidvari AH; Vali Y; Sturm H; Oxman AD
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD006731. PubMed ID: 26239041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.
    Elsisi GH; Anwar MM; Khattab M; Elebrashy I; Wafa A; Elhadad H; Awad M; Carapinha JL
    J Med Econ; 2020 Aug; 23(8):908-914. PubMed ID: 32364032
    [No Abstract]   [Full Text] [Related]  

  • 10. 2016 Writing Contest Undergraduate Winner: The Relationship Between Medication Adherence and Total Healthcare Expenditures by Race/Ethnicity in Patients with Diabetes in Hawai'i.
    Sutton CX; Carpenter DA; Sumida W; Taira D
    Hawaii J Med Public Health; 2017 Jul; 76(7):183-189. PubMed ID: 28721312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct medical cost of diabetes in rural China using electronic insurance claims data and diabetes management data.
    Wu H; Eggleston KN; Zhong J; Hu R; Wang C; Xie K; Chen Y; Chen X; Yu M
    J Diabetes Investig; 2019 Mar; 10(2):531-538. PubMed ID: 29993198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What should be the basis for compulsory and optional health insurance premiums? Opinions of Swiss doctors.
    Jannot AS; Perneger TV
    Swiss Med Wkly; 2014 Feb; 144():w13918. PubMed ID: 24496851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of health care financing on family budgets.
    Rasell E; Bernstein J; Tang K
    Int J Health Serv; 1994; 24(4):691-714. PubMed ID: 7896470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for implementing global budgets.
    Holahan J; Blumberg LJ; Zuckerman S
    Milbank Q; 1994; 72(3):399-429. PubMed ID: 7935240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in Direct Medical Cost and Medications for Managing Diabetes in Beijing, China, 2016 to 2018: Electronic Insurance Data Analysis.
    Guo L; Zheng J; Pan Q; Zhang Q; Zhou Y; Wang W; Zhang L; Tesfaye S; Zhang J
    Ann Fam Med; 2021; 19(4):332-341. PubMed ID: 34264834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A budget impact analysis for making treatment decisions based on anti-cyclic citrullinated peptide (anti-CCP) testing in rheumatoid arthritis.
    Park SH; Han X; Lobo F; Kratochvil D; Patel D
    J Med Econ; 2020 Jun; 23(6):624-630. PubMed ID: 32075453
    [No Abstract]   [Full Text] [Related]  

  • 17. Will health fund rationalisation lead to significant premium reductions?
    Hanning B
    Aust Health Rev; 2003; 26(3):139-46. PubMed ID: 15368829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in the golden state: small-group premiums rise sharply while actuarial values for individual coverage plummet.
    Gabel J; Pickreign J; McDevitt R; Whitmore H; Gandolfo L; Lore R; Wilson K
    Health Aff (Millwood); 2007; 26(4):w488-99. PubMed ID: 17569684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lowering Cost Share May Improve Rates of Home Glucose Monitoring Among Patients with Diabetes Using Insulin.
    Xie Y; Agiro A; Bowman K; DeVries A
    J Manag Care Spec Pharm; 2017 Aug; 23(8):884-891. PubMed ID: 28737991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].
    Danzon PM; Drummond MF; Towse A; Pauly MV
    Value Health; 2018 Feb; 21(2):140-145. PubMed ID: 29477391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.